Koers ReNeuron Group Plc London S.E.
Aandelen
Biotechnologie & Medisch Onderzoek
Omzet 2022 | 403K 505K 468K | Omzet 2023 | 530K 664K 616K | Marktkapitalisatie | 5,17 mln. 6,48 mln. 6,01 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2022 | -9 mln. -11,27 mln. -10,46 mln. | Nettowinst (verlies) 2023 | -5 mln. -6,26 mln. -5,81 mln. | EV/omzet 2022 | 8,48 x |
Nettoliquiditeiten 2022 | 13,99 mln. 17,51 mln. 16,25 mln. | Nettoliquiditeiten 2023 | 6,73 mln. 8,43 mln. 7,82 mln. | EV/omzet 2023 | -2,94 x |
K/w-verhouding 2022 |
-1,79
x | K/w-verhouding 2023 |
-0,96
x | Werknemers | - |
Dividendrendement 2022 * |
-
| Dividendrendement 2023 |
-
| Vrij verhandelbaar | 78,26% |
Recentste transcriptie over ReNeuron Group Plc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Suzanne Hancock
COO | Chief Operating Officer | - | 01-01-17 |
Chief Tech/Sci/R&D Officer | - | 03-03-22 | |
Simon Dew
PRN | Corporate Officer/Principal | - | 01-11-22 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Martin Walton
BRD | Director/Board Member | 61 | 22-03-22 |
Iain Ross
CHM | Chairman | 71 | 01-07-21 |
Director/Board Member | 61 | 14-07-21 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+17,96% | 44,96 mld. | |
+1,17% | 42,65 mld. | |
+48,77% | 41,85 mld. | |
-4,27% | 29,04 mld. | |
+11,42% | 26,08 mld. | |
-21,39% | 19,03 mld. | |
+4,86% | 12,75 mld. | |
+27,29% | 12,06 mld. | |
-3,50% | 11,75 mld. |